##semicolon##
breast cancer; ABO blood group; triple-negative breast cancer; estrogen receptor; progesterone receptor; HER2; Ki-67; molecular subtype; immunohistochemistry.##submission.citations##
1. Abdul-Jabbar, R. A., Ad'hiah, A. H., & Alrekabi, A. N. G. (2013). An evaluation of some risk factors and ABO blood groups in breast cancer patients. Iraqi Journal of Science, 54(Suppl. 4), 1036–1043.
2. Alchazal, R., Zaitoun, K. J., Al-Qudah, M., Zaitoun, G., Taha, A. M., Saleh, O., et al. (2025). Relationship between ABO blood group antigens and Rh factor with breast cancer: A systematic review and meta-analysis. Oncotarget, 16, 311–326. https://doi.org/10.18632/oncotarget.28718
3. Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., et al. (2020). Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. Journal of Clinical Oncology, 38(12), 1346–1366. https://doi.org/ 10.1200/JCO.19.02309
4. Allred, D. C., Harvey, J. M., Berardo, M., & Clark, G. M. (1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology, 11(2), 155–168.
5. Al-Ogla, E. A.-A., Al-Awadi, J. H. H., Mohammed Ali, H. H., & Kehiosh, H. J. (2024). Effect patients' age and ABO blood groups with tumor markers in breast cancer in Kerbala'a governorate. International Journal of Applied Engineering & Technology, 6(1), 1120–1128.
6. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263. https:// doi.org/10.3322/caac.21834
7. DeSantis, C. E., Ma, J., Goding Sauer, A., Newman, L. A., & Jemal, A. (2017). Breast cancer statistics, 2017: Racial disparity in mortality by state. CA: A Cancer Journal for Clinicians, 67(6), 439–448. https://doi.org/10.3322/caac.21412
8. Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., & Panel members. (2013). Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 24(9), 2206–2223. https://doi.org/10.1093/annonc/mdt303
9. Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019). Breast cancer. Nature Reviews Disease Primers, 5, 66. https://doi.org/10.1038/s41572-019-0111-2
10. Khalaf, H., Mohammed, A., Shukur, S., Alhalabi, N., Almothafar, B., Hassan, M., & Abu, A. (2022). Breast cancer: Age incidence, hormone receptor status and family history in Najaf, Iraq. Journal of Medicine and Life, 15(10), 1318–1321. https://doi.org/10.25122/jml-2022-0296
11. Kurbonova, Z. Ch., & Turobova, M. Y. (2026). Clinicopathological features of immunohistochemical marker expression in breast cancer [in Uzbek: Sut bezi saratonida immunogistokimyoviy markerlar ekspressiyasining klinik-patologik xususiyatlari]. Vestnik Assotsiatsii Pul'monologov Tsentral'noy Azii [Bulletin of the Association of Pulmonologists of Central Asia], 16(21), 44–51.
12. Lin, C. H., Yap, Y. S., Lee, K. H., Im, S. A., Naito, Y., Yeo, W., Ueno, T., Kwong, A., Li, H., Huang, S. M., & Leung, R. (2019). Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. JNCI: Journal of the National Cancer Institute, 111(12), 1298–1306. https://doi.org/10.1093/jnci/djz107
13. Loibl, S., & Gianni, L. (2017). HER2-positive breast cancer. The Lancet, 389(10087), 2415–2429. https://doi.org/10.1016/S0140-6736(16)32417-5
14. Lukong, K. E. (2017). Understanding breast cancer: The long and winding road. BBA Clinical, 7, 64–77. https://doi.org/10.1016/j.bbacli.2017.01.001
15. Menon, S. S., Guruvayoorappan, C., Sakthivel, K. M., & Rasmi, R. R. (2019). Ki-67 protein as a tumour proliferation marker. Clinica Chimica Acta, 491, 39–45. https://doi.org/ 10.1016/j.cca.2019.01.011
16. Meo, S. A., Suraya, F., Jamil, B., Al Rouq, F., Meo, A. S., Sattar, K., & Alasiri, S. A. (2017). Association of ABO and Rh blood groups with breast cancer. Saudi Journal of Biological Sciences, 24(7), 1609–1613. https://doi.org/10.1016/j.sjbs.2017.05.004
17. Nielsen, T. O., Leung, S. C. Y., Rimm, D. L., Dodson, A., Acs, B., Badve, S., et al. (2021). Assessment of Ki67 in breast cancer: Updated recommendations from the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 113(7), 808–819. https:// doi.org/10.1093/jnci/djaa201
18. Patel, B. (2019). A review of breast cancer and hormonal therapy. International Journal of Pharmaceutical Sciences and Research, 10, 519–527.
19. Sauter, E. R. (2017). Reliable biomarkers to identify new and recurrent cancer. European Journal of Breast Health, 13(4), 162–167. https://doi.org/10.5152/ejbh.2017.3600
20. Schick, J., Ritchie, R. P., & Restini, C. (2021). Breast cancer therapeutics and biomarkers: Past, present, and future approaches. Breast Cancer: Basic and Clinical Research, 15, 117822 3421995854. https://doi.org/10.1177/1178223421995854
21. Wolff, A. C., Somerfield, M. R., Dowsett, M., Hammond, M. E. H., Hayes, D. F., McShane, L. M., et al. (2023). Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists guideline update. Journal of Clinical Oncology, 41(22), 3867–3872. https://doi.org/10.1200/JCO.22.02864